StockData
Latigo Biotherapeutics, Inc. logo

Latigo Biotherapeutics, Inc. (LTGO) stock

LTGONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026
$13.24−0.07 (-0.53%)

Close on Nov 19, 2026Market cap $877.80MP/E –Yield 0.00%

Latigo Biotherapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$19.56M–
Q3 FY2025Sep 30, 2025-$19.91M–

More Latigo Biotherapeutics figures

See a number that looks wrong?